Antibody targeting through a modular recognition domain

Patent metadata

Field	Value
Publication number	US-10030051-B2
Application number	US-201514963722-A
Country	US
Kind code	B2
Filing date	Dec 9, 2015
Priority date	Jan 3, 2008
Publication date	Jul 24, 2018
Grant date	Jul 24, 2018

Abstract

The present invention provides antibodies containing one or more modular recognition domains (MRDs) for targeting the antibodies to specific sites. The use of the antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also provided in the invention.

First claim

What is claimed is:

1. An antibody fusion protein comprising a full length antibody and a modular recognition domain (MRD), wherein the MRD binds to integrin and consists of the amino acid sequence set forth in any one of SEQ ID NOs: 3-6, wherein the MRD is operably linked to the antibody, and wherein the antibody binds to ErbB2.

2. The antibody fusion protein of claim 1 , wherein the antibody and the MRD are operably linked through a linker peptide.

3. The antibody fusion protein of claim 2 , wherein the linker peptide comprises a sequence selected from the group consisting of: GGGS (SEQ ID NO: 1), SSGGGGSGGGGGGSS (SEQ ID NO: 2), and SSGGGGSGGGGGGSSRSS (SEQ ID NO: 19).

4. The antibody fusion protein of claim 1 , wherein the MRD is operably linked to the C-terminal end of the heavy chain of the antibody, the N-terminal end of the heavy chain of the antibody, the C-terminal end of the light chain of the antibody, or the N-terminal end of the light chain of the antibody.

5. The antibody fusion protein of claim 1 , wherein the antibody is a chimeric or humanized antibody.

6. The antibody fusion protein of claim 1 , wherein the antibody is Trastuzumab.

7. The antibody fusion protein of claim 2 , wherein the antibody is a chimeric or humanized antibody.

8. The antibody fusion protein of claim 2 , wherein the antibody is Trastuzumab.

9. A method of treating a disease characterized by undesired angiogenesis, comprising administering to a subject in need thereof the antibody fusion protein of claim 1 .

Assignees

• Scripps Research Inst

Inventors

• Barbas Iii Carlos F

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title

• C07K2319/70

  containing domain for protein-protein interaction · CPC title

• C07K7/08

  having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title